Treatment of localized-stage follicular lymphoma
نویسندگان
چکیده
منابع مشابه
Treatment of follicular lymphoma.
Follicular lymphoma (FL) is the most common subtype of indolent lymphomas. Several lines of evidence suggest that the prognosis of patients with FL has improved since the introduction of rituximab, although cure cannot be achieved. Although the treatment paradigm for FL has changed over the past decade with the introduction of rituximab and other agents, there is still no standard therapy to fi...
متن کاملRadiation therapy for localized duodenal low-grade follicular lymphoma
The aim of this study was to evaluate the initial treatment results and toxicities of radiation therapy for patients with early stage low-grade follicular lymphoma (FL) arising from the duodenum. We reviewed 21 consecutive patients with early stage duodenal FL treated with radiation therapy between January 2005 and December 2013 at the Cancer Institute Hospital, Tokyo. The characteristics of pa...
متن کاملDiagnosis and treatment of follicular lymphoma.
Follicular lymphoma is a slow-growing disease exhibiting a heterogeneous clinical course, with a subset of patients experiencing a rapid disease course in the first two years and some developing disease transformation to a more aggressive phenotype. The advent of highly effective therapies has resulted in an increasing number of patients who achieve long-term progression-free survival alongside...
متن کاملLimited Stage Follicular Lymphoma: Current Role of Radiation Therapy
Radiation therapy (RT) alone has been considered for a long time as the standard therapeutic option for limited stage FL, due to its high efficacy in terms of local disease control with a quite significant proportion of "cured" patients (without further relapses at 10-15 years). Multiple therapeutic choices are currently accepted for the management of early stage FL at diagnosis, and better sta...
متن کاملRituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
This paper presents a summary of the evidence review group report into the clinical effectiveness and cost-effectiveness of rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (NHL), in accordance with the licensed indication, based upon the evidence submission from Roche Products Ltd to the National Institute for Health and Clinical Excellenc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Haematology
سال: 2018
ISSN: 0902-4441
DOI: 10.1111/ejh.13093